All News
Abatacept Efficacy in JIA
Subcutaneous abatacept (Orencia) showed efficacy among children with polyarticular juvenile idiopathic arthritis (JIA) in an open-label phase III trial.
Read Article
Severe Stevens-Johnson and Toxic Epidermal Necrolysis Syndromes May Respond to Etanercept
The Journal of Clinical Investigation reports the results of a trial wherein etanercept (ETN) was shown to be effective in treating cytotoxic T lymphocyte–mediated (CTL-mediated) severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (T
Read Article
The RheumNow Week in Review - 2 March 2018
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com.
Read Article
Inflammatory Arthritis Variants with Checkpoint Inhibitors
Capelli and colleagues have studied patients treated with ICIs and found two variants of inflammatory arthritis (IA) - a reactive arthritis like large joint arthritis with combination ICI therapy or a small joint IA with ICI monotherapy.
Read Article
IL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18 binding protein, tadekinig alfa, demonstrating its effectiveness in an open-label dose escalating study in patients with adult-onset Still's disease (AOSD).
Read Article
The RheumNow Week in Review - 23 February 2018
Dr Jack Cush reviews highlights from the past week on RheumNow.com. This week’s video is in two parts; for part Ii, go to https://buff.ly/2BM9MjL
Read Article
Apremilast Continues to Look Good in Behcet's Disease
The 2018 American Academy of Dermatology Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.
Read Article
RWCS Day 3 Podcast
Listen in on the proceedings from the 2018 RWCS meeting in Maui with excerpts from leading teachers in rheumatology. This podcast features topics in dermatology, the fellowship program lead by Dr. Bernie Rubin and videos by the fellows. Featured are Drs.
Read Article
RWCS Day 1 Podcast
Listen in on the proceedings from RWCS with excerpts from leading teachers in rheumatology. This podcast features Drs. Bevra Hahn, Artie Kavanaugh and Anne Stevens.
Read Article
The RheumNow Week in Review - 2 February 2018
Dr. Jack Cush reviews highlights, news and recent research published this week on RheumNow.com. This week's report includes rising epidemiologic numbers, vaccine updates for H.
Read Article
Inefficacy of Immunosuppressive Treatments in Systemic Sclerosis with ILD
EUSTAR study results published in Arthritis Research & Therapy show the current state of immunosuppressive use in systemic sclerosis patients with interstitial lung disease (SSc-ILD) to be ill-defined, but that liberal use of glucocorticoids (GC) in SSc-ILD should be discouraged
Read Article
ESRD Death Declines in Vasculitis Patients
In the past 2 decades, mortality from end-stage renal disease (ESRD) among U.S. patients with granulomatosis with polyangiitis (GPA) has declined significantly, a nationwide study found.
Read Article
The RheumNow Week in Review - 26 January 2018
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report covers the price of biologics treatment in psoriasis, comorbidities in myositis, bronchiectasis with MPO antibodies, and the risk of secondary TNF failure with anti-drug antibodies.
Read Article
IL-1 and IL-6 Inhibition Preferred in Systemic JIA
Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic arthritis to assess outcomes with biologic therapies. A new report evaluates the efficacy and safety of etanercept (ETA), tocilizumab (TOC) and the interleukin-1 inhibitors (anakin
Read Article
The RheumNow Week in Review - 12 January 2018
Dr. Jack Cush reviews a dozen highlights from the past week on RheumNow.com.
Read Article
B Cell Changes Predict Autoimmunity with Checkpoint Inhibitors
The Journal of Clinical Investigation reports results of a study showing that increases in CD21lo B cells and plasmablasts following that combination checkpoint blockade preceded the onset of immune-related adverse events.
While some have postulated that IRAEs are thought to be T cell mediated, B cells have also been implicated. Investigators studied 39 melanoma patients undergoing treatment with either anti-CTLA4 or anti-PD1, or combination CCB therapy. They analyzed changes in circulating B cells before and after the first cycle of therapy of immune checkpoint blockade (23 received combination therapy, 8 received anti-CTLA4, and 8 received anti-PD1).
Read Article
Stem Cell Transplant Succeeds in Scleroderma
Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.
Read Article
The RheumNow Week in Review - 15 December 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com.
Read Article
Offspring of RA Women Have Higher Risk of RA and Other Diseases
Despite a growing body of evidence suggesting that maternal health is more important than maternal medications to fetal and infant outcomes, little is known about the long term oucomes of infants born to mothers with rheumatoid arthritis (RA). Using Danish population data, researchers have shown in utero exposure to maternal RA is associated with an increased risk of thyroid disease, and an increased risk of future RA.
Read Article